Ken Griffin’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-269,389
| Closed | -$59.5M | – | 13085 |
|
|
2025
Q4 | $59.5M | Sell |
269,389
-324,604
| -55% | -$52.5M | 0.01% | 1267 |
|
|
2025
Q3 | $56.9M | Buy |
593,993
+303,042
| +104% | +$19.3M | 0.01% | 1266 |
|
|
2025
Q2 | $14.2M | Buy |
290,951
+3,176
| +1% | +$76.3K | ﹤0.01% | 2586 |
|
|
2025
Q1 | $6.2M | Buy |
+287,775
| New | +$6.39M | ﹤0.01% | 3542 |
|
|
2024
Q2 | – | Sell |
-4,227
| Closed | -$77.8K | – | 14329 |
|
|
2024
Q1 | $77.8K | Buy |
+4,227
| New | +$60.7K | ﹤0.01% | 11693 |
|
|
2023
Q1 | – | Sell |
-15,081
| Closed | -$428K | – | 14774 |
|
|
2022
Q4 | $228K | Buy |
+15,081
| New | +$180K | ﹤0.01% | 9877 |
|
|
2022
Q3 | – | Sell |
-2,868
| Closed | -$39.6K | – | 12691 |
|
|
2022
Q2 | $28K | Buy |
+2,868
| New | +$35.4K | ﹤0.01% | 12258 |
|
|
2022
Q1 | – | Sell |
-6,309
| Closed | -$107K | – | 13658 |
|
|
2021
Q4 | $161K | Buy |
6,309
+5,027
| +392% | +$156K | ﹤0.01% | 12173 |
|
|
2021
Q3 | $57K | Buy |
1,282
+639
| +99% | +$24.3K | ﹤0.01% | 13290 |
|
|
2021
Q2 | $26K | Sell |
643
-424
| -40% | -$17.9K | ﹤0.01% | 13506 |
|
|
2021
Q1 | $57K | Buy |
+1,067
| New | +$52.7K | ﹤0.01% | 12836 |
|
|
2020
Q2 | – | Sell |
-522
| Closed | -$26K | – | 9821 |
|
|
2020
Q1 | $26K | Sell |
522
-448
| -46% | -$26.8K | ﹤0.01% | 9230 |
|
|
2019
Q4 | $74K | Buy |
+970
| New | +$44.4K | ﹤0.01% | 8655 |
|
|
2018
Q2 | – | Sell |
-732
| Closed | -$59K | – | 8840 |
|
|
2018
Q1 | $59K | Buy |
+732
| New | +$100K | ﹤0.01% | 7879 |
|
|
2017
Q3 | – | Sell |
-857
| Closed | -$129K | – | 7559 |
|
|
2017
Q2 | $129K | Buy |
+857
| New | +$118K | ﹤0.01% | 6817 |
|
|
2015
Q4 | – | Sell |
-1,220
| Closed | -$310K | – | 8747 |
|
|
2015
Q3 | $310K | Buy |
1,220
+60
| +5% | +$17.2K | ﹤0.01% | 5510 |
|
|
2015
Q2 | $325K | Buy |
+1,160
| New | +$357K | ﹤0.01% | 5640 |
|
Ken Griffin's CDTX Position: Q1 2026 in Review
Ken Griffin sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 269,389 shares — an estimated $59.5M sold.
Ken Griffin first reported a position in CDTX in Q2 2015 and held it in 17 quarters. The position peaked at $59.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Ken Griffin reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Ken Griffin sold 269,389 Cidara Therapeutics shares in Q1 2026, an estimated $59.5M.
- Ken Griffin first reported a position in Cidara Therapeutics in Q2 2015 and held it in 17 quarters.
- Ken Griffin's Cidara Therapeutics position peaked at $59.5M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.